SY-LB-35, a potent bone morphogenetic protein (BMP) receptor agonist, significantly enhances cell number and viability in the C2C12 myoblast cell line. It promotes cell cycle progression, particularly towards the S and G2/M phases. Additionally, SY-LB-35 activates both canonical Smad and non-canonical intracellular signaling pathways, including PI3K/Akt, ERK, p38, and JNK [1].

SY-LB-35, at concentrations ranging from 0.01 to 1000 μM applied for 24 hours, significantly enhances both the number and viability of C2C12 myoblast cells [1]. At reduced concentrations (0.01-10 μM) and shorter exposure times (30 or 15 minutes), it promotes Smad phosphorylation and its nuclear translocation, while also activating the PI3K/Akt signaling pathway and influencing the localization of phosphorylated Akt within the cytoplasm. Moreover, this treatment boosts PI3K phosphorylation and activation in these cells. Additionally, SY-LB-35, at concentrations of 0.01-10 μM for 24 hours, induces a shift in the cell cycle towards the S and G2/M phases in C2C12 cells [1]. Through cell viability assays, it was established that SY-LB-35 at concentrations of 0.01 to 1000 μM over 24 hours considerably increases cell count and viability. Further analysis via Western Blot and cell cycle assessment corroborated its role in stimulating key signaling pathways and effecting cell cycle progression at concentrations of 0.01 to 10 μM over durations of 15 to 30 minutes and 24 hours, respectively.